Quantitative and comparative analysis of urinary steroid levels upon treatment of an anti-diabetic drug, CKD-501 using gas chromatography-mass spectrometry
- Quantitative and comparative analysis of urinary steroid levels upon treatment of an anti-diabetic drug, CKD-501 using gas chromatography-mass spectrometry
- 크리쉬나; 정병화; 장인진; 정봉철
- CKD-501; diabetes; steroid; GC-MS; PPAR (Peroxisome proliferator-activated receptor)
- Issue Date
- Journal of Pharmaceutical Investigation
- VOL 41, NO 1, 37-43
- Urinary steroid levels were investigated in the treatment of CKD-501, a new anti-diabetic drug candidate.
CKD-501 was administered orally at the dosage of 1, 2, 4 mg/day for 7 days to normal men (n=18). Urine was collected
before, during and after stopping the drug administration and the urinary level of androgen, estrogen, progestin and corticoids
were quantified using GC-MS (gas chromatography-mass spectrometry). Only urinary corticosteroid and an androgen,
DHEA levels among all the analyzed steroids, have been found to increase progressively, reaching significant levels
on the last day of drug treatment and later declined after the drug treatment is withdrawn. Therefore, it was thought that
an increase in the urinary corticoid and DHEA levels could be a characteristic of CKD-501, since it prominently acts on
the glucose sensitivity and suppresses the triglyceride levels. In conclusion, it was found that CKD-501, an anti-diabetic drug
candidate, affects the glucocorticoid and DHEA levels and it plays a crucial role in glucose homeostasis.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.